Wanbury’s API manufacturing facility at Tanuku, Andhra Pradesh, has successfully completed a three-day cGMP inspection conducted by the Ministry of Food and Drug Safety (MFDS), Republic of Korea, with zero observations. This achievement follows the successful completion of a South Korea MFDS cGMP inspection at the company’s Patalganga manufacturing facility in April 2026, which was also concluded with zero observations.
Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.